etopophos and sprycel Interactions

You searched for interactions between:

• etopophos
• sprycel (dasatinib)

Interaction(s) found:

dasatinib and etoposide phosphate (Moderate Drug-Drug)

MONITOR: Coadministration with dasatinib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by dasatinib, which is a time-dependent inhibitor of the isoenzyme. In a pharmacokinetic study of 54 healthy subjects, administration of simvastatin with a single 100 mg dose of dasatinib resulted in a 37% and 20% increase in simvastatin peak plasma concentration (Cmax) and systemic exposure (AUC), respectively, compared to administration without dasatinib. Other CYP450 3A4 substrates may be similarly affected.

MANAGEMENT: Caution is advised if dasatinib must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dasatinib is added to or withdrawn from therapy.